Phase II Trial of Trimetrexate in Patients with Stage III and IV Non-Small-Cell Lung Cancer
Authors:
- Robert W. DʼacquistoRDRobert W. Dʼacquisto
- Richard J. GrallaRGRichard J. Gralla
- M Thomasine BurkeMBM Thomasine Burke
- Linda D. MarksLMLinda D. Marks
- Michael P. FanucchiMFMichael P. Fanucchi
- Robert T. HeelanRHRobert T. Heelan
- 1 February 1989
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 12 (1) , 24-26
Abstract
Trimetrexate is a nonclassical antifolate with greater preclinical antitumor activity than methotrexate. Fourteen patients with stage III or IV non-small-cell lung cancer who had not previously received chemotherapy were given trimetrexate (12 mg/m2 intravenously daily for 5 days) every 3 weeks. No major objective responses were observed (95% confidence limits: 0-20%). Ten of the 14 patients had grade 2 or greater toxicity, with 50% experiencing grade 2 or greater leukopenia and/or thrombocytopenia. Nausea, vomiting, rash, mucositis, diarrhea, and serum glutamic-oxaloacetic transaminase (SGOT) elevations were also seen. At the dosage and schedule of trimetrexate used, no responses occurred in this population of patients with non-small-cell lung cancer. With the low response rate and the observed degree of myelosuppression, trimetrexate appears to have limited utility in this disease.Keywords
This publication has 12 references indexed in Scilit:
- PHASE-I STUDIES WITH TRIMETREXATE - CLINICAL-PHARMACOLOGY, ANALYTICAL METHODOLOGY, AND PHARMACOKINETICS1987
- RANDOMIZED TRIAL COMPARING VINDESINE PLUS CISPLATIN WITH VINBLASTINE PLUS CISPLATIN IN PATIENTS WITH NON-SMALL CELL LUNG-CANCER, WITH AN ANALYSIS OF METHODS OF RESPONSE ASSESSMENT1985
- High-dose methotrexate with leucovorin rescue in patients with unresectable non-small cell carcinoma of the lungCancer, 1983
- RANDOMIZED PHASE-II COMPARISON OF METHOTREXATE WITH OR WITHOUT L-ASPARAGINASE IN NON-SMALL CELL-CANCER OF THE LUNG1982
- PHASE-II EVALUATION OF METOPRINE IN PATIENTS WITH NON-SMALL-CELL LUNG-CARCINOMA1981
- PHASE-II STUDY OF HIGH-DOSE METHOTREXATE IN THE TREATMENT OF PATIENTS WITH NON-SMALL CELL-CARCINOMA OF THE LUNG - AN EASTERN COOPERATIVE ONCOLOGY GROUP-STUDY1980
- Evaluation of response criteria in advanced lung cancerCancer, 1979
- 2,4-Diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl]quinazoline (TMQ), a potent non-classical folate antagonist inhibitor—IBiochemical Pharmacology, 1979
- Oral high-dose methotrexate with citrovorum factor rescue in metastatic squamous cell carcinoma of the lungCancer, 1978
- Methotrexate compared with placebo in lung cancerCancer, 1977